T-cell immunotherapy is a rapidly emerging field of oncology. T-cell therapies have come out as a promising option among the current targeted anti-cancer therapies due to their high target specificity, customization potential, ability to generate immunological memory, and minimal side effects. Some of the novel types of T-cell therapies are γδ T-cells, Tregs, activated T-cells, virus-driven T-cells, and T-cell vaccines. The gamma delta T cell therapies have shown high efficacy and specificity towards cancer cells in clinical trials compared to other conventional cancer therapies.
The primary approach of T-cells therapy is identifying the cancer-causing cells and developing a strong immune response against the cells without causing side effects. The increasing prevalence of chronic diseases is expected to propel the novel T-cell immunotherapies market growth over the forecast period. In addition, multiple collaborations between various therapy developers and research institutes/universities to develop innovative therapies support the market growth.
The increasing need for cell and gene therapies, the high prevalence of cancer, and the rising number of clinical trials will boost the market growth opportunities in the coming days. Furthermore, advanced medical technologies, a rise in the geriatric population, and a growing number of health-conscious people enhance the novel T-cell immunotherapies market development. However, the high investment cost required for therapy development, lack of standard therapy protocols, and shortage of skilled professionals restrain the market growth.
Segmentation of novel T-cell immunotherapies market includes Type of T-cell Therapy, Disease Indication, and Region. By Type of T-cell Therapy, the market can be segmented into Activated T-cells, Virus Driven T-cells, Tregs, γδ T-cells, T-cell vaccines, and NK T-cells. Based on Disease Indication, the market is segmented into Lung cancer, Breast Cancer, Cytomegalovirus Infection, Glioblastoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia, Ovarian Cancer, Type 1 Diabetes Mellitus, Sarcoma, HIV infections, Pancreatic Cancer, and Others. Various types of cancer drive the growth of this market. Regionally, the novel T-cell immunotherapies market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe, holds the maximum share of this market due to increased research and development expenditure, the presence of major market players, and the fast adoption of advanced technologies.